Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; CALCULATION; CANCER SURVIVAL; CONFIDENCE INTERVAL; HAZARD RATIO; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; MATHEMATICAL COMPUTING; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; MATHEMATICAL COMPUTING; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84939424687     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv153     Document Type: Article

References (5)

1. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford, UK: Oxford University Press, 2003.
2. Sitlani CM, Haegerty PJ. Analyzing longitudinal data to characterize the accuracy of markers used to select treatment. Stat in Med. 2014;33:2881-2896.
3. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
4. Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. Biometrics. 2012;68:687-696.
5. Marshall AW, Olkin I. A generalized bivariate exponential distribution. J Appl Probab. 1967;4:291-302.